Single-nucleotide polymorphisms (SNPs) within the tumour necrosis factor alpha (TNF-a) gene on chromosome 6p21.3 have been associated with many autoimmune diseases; however, results have been conflicting and accurate allele frequencies have never been established in a UK Caucasian population. The aim of this study was to assess the frequency of 22 known TNF-a SNPs in a UK Caucasian control population and investigate association of all polymorphisms with 45% minor allele frequency in a large case-control data set of patients with Graves' disease (GD). Eight of the 22 SNPs had minor allele frequencies 45% and were investigated further. The other 14 SNPs were present in the UK population at frequencies ranging from 0 to 4.7%. A significant increase of the A allele of the À238 SNP was seen in GD patients when compared with control subjects (9.6 vs 6.8%, respectively; P ¼ 0.003) and mirrored in the genotype distribution (P ¼ 0.009). Furthermore, association of the -238 SNP appears not to be due to linkage disequilibrium of the known HLA-DRB1*03 associations with GD. This study has established accurate allele frequencies of TNF-a SNPs in a UK population and provides preliminary evidence for association of the TNF-a gene with GD.
Introduction
Graves' disease (GD) is a common autoimmune disorder that affects 0.5-1% of the general population. 1 Its aetiology is unknown, but is thought to be caused by a complex interaction between genetic and environmental factors. 2 Many environmental agents have been postulated to influence the development of GD, including stressful life events, 3 iodine intake 4 and bacterial or viral infection, 5 but to date no conclusive evidence favouring any of these factors has been produced. Many genetic studies have been performed, but only the human leukocyte antigen (HLA) gene region of the major histocompatibility complex (MHC) on chromosome 6p21 6, 7 and the cytotoxic T lymphocyte associated (CTLA-4) gene on chromosome 2q33 8, 9 have been consistently shown to be associated with GD. Collectively, these loci are likely to contribute to less than 50% of the genetic susceptibility to GD in the UK, leaving at least 50% unaccounted for. 10 Genome wide screens conducted in GD have identified a number of regions of linkage 11, 12 although independent replication and novel candidate loci are awaited.
Attention within the HLA gene region has been mainly focussed on the class II genes, in particular DR and DQ. Little work has been performed on the Class III genes (see Figure 1) , which include components of the complement system, the heat shock proteins and the tumour necrosis factors including tumour necrosis factor-alpha (TNF-a). TNF-a, on chromosome 6p21.3, is an important multifunctional cytokine secreted by macrophages and T lymphocytes with wide-ranging biological effects including protection from infection, surveillance against tumours and stimulation of inflammatory responses. TNF-a is composed of four exons arranged over approximately 3 kb of DNA. 13 Regulation of TNF-a production occurs at both transcriptional and post-transcriptional levels, with regulatory sequences within the 5 0 end of the gene controlling the rate of transcription.
14 Single-nucleotide polymorphisms (SNPs) within TNF-a have the potential to cause structural changes within regulatory sites that could affect the function or regulation of TNF-a production. These factors combined could contribute to the autoimmune process making it an ideal candidate for the development of GD.
A number of SNPs have been detected in TNF-a both within the promoter and the gene itself (see Figure 2 where all SNPs are referred to by their classical, although strictly incorrect numbering system, as it has been shown that when originally classified, the -308 and -238 SNPs were classified at À1 nucleotide greater than their true position 15 ). Studies looking for association with disease have been performed only in small ethnically diverse data sets of different autoimmune diseases, including rheumatoid arthritis, 16 Crohn's disease 17 and systemic lupus erythematosus. 18 Results are conflicting and accurate allele frequencies remain unknown, making meaningful interpretation of the data difficult.
In the current study we investigated 22 previously published SNPs of TNF-a. Allele frequencies were initially determined for all SNPs in 96 UK Caucasian controls. All SNPs showing an allele frequency of 45% were then taken forward into a case-control association study of 864 patients with GD and 864 ethnically matched controls. Linkage disequilibrium (LD) between the SNPs was determined. LD between the associated SNPs and the HLA-DRB1*03-DQB1*02-DQA1*0501 extended haplotype was also calculated to determine whether association with disease was due to the strong and well-established association between GD and the HLA-DRB1*03 extended haplotype.
Results
Allele frequency assessment of TNF-a SNPs in a UK Caucasian population Allele frequencies for the twenty two known TNF-a SNPs were initially investigated in 96 control subjects of UK Caucasian origin and the results are shown in Table 1 . Of the twenty two SNPs investigated, eight SNPs had minor allele frequencies above 5% (Table 1 , in bold), with frequencies ranging from 6.7% ( þ 851) to 26.5% (À308). Of the remaining SNPs, ten were found to be nonpolymorphic in the UK population tested and four were present, but with minor allele frequencies below 5% Figure 1 Simplified diagram of the HLA region on chromosome 6q21, highlighting the different genes present within the HLA class III region that could be contributing to disease association. Figure 2 TNF-a gene structure and known polymorphims. All SNPS are referred to by their classical, although strictly incorrect numbering system, the À308 and À238 SNPs were originally classified at À1 nucleotide greater than their true position. 
SNPs highlighted in bold had minor allele frequencies 45%.
TNF-a polymorphisms in Graves' disease MJ Simmonds et al (Table 1 ). Power calculations indicated that for an odds ratio (OR) of 1.5 and a significance level of 0.05, our data set of 864 GD patients and 864 control subjects provided 80% power to detect a significant association of a polymorphism with disease, if present, for those polymorphisms with minor allele frequencies of 5% or greater. We therefore took forward only the eight SNPs with minor allele frequencies of 45% for genotyping within our case-control data set.
Genotyping results in the case-control data set Allele frequencies for all eight SNPs genotyped are shown in Table 2 . A significant increase in the A allele of the À238 SNP and the C allele of the À1031 SNP was seen in patients with GD when compared with control subjects (P ¼ 0.003 and 0.046, respectively; Table 2 , in bold). A significant difference in genotype distribution of the -238 SNP was also shown between patients with GD and control subjects, but the -1031 genotype distribution had a nonsignificant P-value as shown in Table 3 . Further calculations performed on SNPs based on the ORs calculated from our data showed that we had 86% power to exclude an effect equivalent to the À238 and 59% power for an effect equivalent to the À1031. No other SNPs were shown to be associated with disease ( Table 2 ) and both cases and controls were in HardyWeinberg equilibrium.
LD between TNF-a SNPs and HLA-DRB1*03
Due to the strong LD found within the MHC region on chromosome 6p21, we assessed whether the association with GD seen with the A allele of the À238 SNP and the C allele of the -1031 SNP was independent of the known association of the HLA-DRB1*03-DQB1*02-DQA1*0501 haplotype or secondary to LD. The HLA-DRB1*03-DQB1*02-DQA1*0501 haplotype was present in 47% of our GD patients and 24% of our control population. 7 LD was assessed between the markers using the cocaphase haplotype analysis program (as described previously 8 ).
Minimal LD was observed between the À238 SNP and HLA-DRB1*03 with a D 0 value of 0.14 and for the À1031 SNP LD was incomplete 0.68, respectively (D 0 ¼ 1 is complete LD).
Pairwise LD between TNF-a SNPs LD was assessed between the eight TNF-a SNPs genotyped within our data set using the cocaphase haplotype analysis programme. 8 D 0 values are shown in Table 4 and D 0 values 40.8 indicate strong LD (values in bold). Complete LD was detected between the following SNPs: þ 489 and þ 1304; À857 and À863; À857 and þ 851; þ 489 and þ 851. Patterns of strong LD (D 0 values above 0.8) were found within our UK Caucasian data set between the þ 489, þ 1304, À857, À863 and þ 851, and À1031, þ 489, À857 and À863 SNPs. No appreciable LD was observed between the -238 SNP and any other SNP typed. This is in contrast to previous studies that have shown À238 to be in lose LD with þ 851. 19 The -1031, unlike the À238, shows patterns of strong LD with the þ 489, À857 and À863 SNPs but does not appear to be in LD with the -238, À308, þ 851 and þ 1304 SNPs.
Discussion
Results generated from small, nonethnically matched case-control data sets have produced confusing and conflicting results regarding the role of TNF-a polymorphisms in the genetic susceptibility to autoimmune disease in the UK Caucasian population. This study is the most comprehensive study, to our knowledge, of TNF-a SNP population frequencies within a control UK Caucasian population and has thus provided control allele frequencies for twenty-two known TNF-a SNPs.
Large numbers of putative SNPs are currently being deposited in electronic databases, although many have not been validated in population based data sets. Out of a total of twenty-two known SNPs in the TNF-a gene, ten (45.5%) of these were not found to be polymorphic in our Caucasian controls and a further four (18%) had minor allele frequencies of o5%, leaving only eight (36%) of those originally identified, as being useful for our casecontrol study. Such 'fall-out' of useful SNP markers has important implications for the study of polygenes in complex disease. A number of strategies for SNP detection and validation are available and the current study highlights the importance of the deposition of validated SNPs in the public domain.
The -238 minor A allele has been shown to be associated with GD within our UK Caucasian population. The region between À254 to À230 contains a regulatory sequence that acts as a TNF-a repressor site. 20 Bayley et al 21 transfected the T cell line Jurkat, B cell line Raji and monocytic cell line U937 with a series of mutant constructs within this repressor region, including one where the -238G allele was replaced by a 10 bp linker sequence containing the -238A mutant allele and tested for differences in basal and induced transcriptional activity. No significant difference in basal or inducible promoter activity in the Jurkat cell line was detected but U937 and Raji cells containing the -238 minor A allele construct showed consistent increases in both basal and inducible activity in all experiments and when incubated for 18 h in medium alone, a consistent and statistically significant (Po0.0005 to o0.005) 1.4-to 1.8-fold increase in basal transcription was detected. 21 This suggests that the -238 SNP and the region surrounding it could be important in TNF-a regulation via a method of repression, and a mutation at position -238 could disrupt regulation and, therefore, potentially account for its association with GD.
The À1031 was the only other SNP to produce weak evidence for association with disease, and as association was not seen in the genotype data it is possible that this is a random chance event. Clearly, further analysis of GD and other diseases with large data sets will be required to determine whether this SNP is conferring susceptibility to autoimmune disease.
Alleles of the À238 and À1031 SNP were shown not to be in LD with the GD associated haplotype HLA-DRB1*03-DQB1*02-DQA1*0501. As this extended haplotype has been consistently reported to be associated with GD in most, 7, 9 but not all, 22, 23 ethnic groups and because LD is strong across the HLA region it is important to exclude the HLA-DRB1*03 haplotype as the explanation for association with the TNF-a SNPs. Furthermore, the HLA-DRB1*03 haplotype is also associated with an increase in TNF-a production. 24 Our data, however, support the hypothesis that association of the -238 SNP with GD is not secondary to LD with the HLA class II loci.
While the À238 SNP may have functional consequences, it is important to investigate all SNPs within the region of LD. A recently published fine mapping strategy of the CTLA-4 gene on chromosome 2q33 demonstrated 
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TNF-a polymorphisms in Graves' disease MJ Simmonds et al the importance of such an approach. The originally associated polymorphic site in the 3 0 UTR of CTLA-4, which clearly had functional consequences, was shown not to be within the 6.1 kb region of primary association. 8 LD within the human genome occurs within a system of large blocks of low recombination or frozen LD, punctuated by 'hot spots'of recombination. [25] [26] [27] LD blocks in general spread across 5-20 kb 25 but have been shown to span across distances from 3 to 92 kb. 28 LD has been shown to occur between polymorphisms within TNF-a and other class II genes. For example, TNF-a SNP À308A is always accompanied by three polymorphisms of lymphotoxin-alpha (LTA), LTA10A, LTA252G and LTA723A genes. 29 Following recent advances in SNP maps of the HLA class III region 19, 30 and the discovery of novel loci, further investigation of other class III genes and the associated -238 SNP will be required to determine the primary susceptibility locus in this gene region.
There is much debate as to whether susceptibility to complex diseases such as GD are caused by common alleles or by several rare variants. 31, 32 In complex diseases such as GD, 50% of the genetic susceptibility may be explained by HLA-DR3 and CTLA-4, 10 and it is likely that the rest of the genetic susceptibility will be caused by several genes of similar or smaller effects. The ORs produced by the -238 and -1031 SNPs of 1.47 and 1.2, respectively, are consistent with this hypothesis. This is the first time that the -238 and -1031 SNPs have been investigated in a UK Caucasian data set of this magnitude, and the result could have been overestimated by the first time effect phenomenonthat occurs when association of a gene is first detected with a complex disease. A meta-analysis of 379 studies addressing 36 genetic associations with disease found that association studies of the same disease are often inconsistent in their findings, and that the first study to report an association often indicates a stronger effect than in subsequent studies. 33 This can lead to a distorted impression of the genetic aetiology underlying a given disease. Power calculations prior to the execution of this study indicated that we had over 80% power to detect association of an SNP of 45% frequency with an OR ¼ 1.5. Importantly our most associated SNP (À238) produced an OR of 1.46, P ¼ 0.003. The ongoing UK Caucasian collection of cell line DNA from subjects with autoimmune thyroid disease (ATD), whose aim is to provide 4000 samples from subjects with ATD and 800 families for the purpose of replication, and exclusion of population stratification, will be useful in confirming or refuting our findings.
Materials and methods

Subjects
Unrelated white Caucasian patients of UK origin with GD were recruited from large thyroid clinics in Birmingham, Walsall, Bournemouth and Exeter, UK, as previously described. 7 Patients were defined as having GD by the presence of biochemical hyperthyroidism together with two of the following criteria: diffuse goitre, a significant titre of microsomal, thyroglobulin, or TSH receptor autoantibodies, and the presence of dysthyroid eye disease. Microsomal and thyroglobulin antibodies were measured by gelatin particle agglutination (SER-ODIA_ATG, Fujirebio, Inc., Tokyo, Japan), and a titre of 1 : 100 was considered significant for both assays. TSH receptor autoantibody status was determined by a radioactive inhibition method (RSR Ltd., Cardiff, UK). Serum-free T 4 concentrations were measured by Amerlex M RIA (Kodak Clinical Diagnostics, Bucks, UK; normal range, 9-24 pmol/l). Ethnically matched control subjects with no family history of autoimmune disease were bled at several sites: Blood Transfusion Services (Birmingham, UK and Oxford, UK), Birmingham Heartlands Hospital, and the Queen Elizabeth Hospital (Birmingham, UK).
In total, DNA was obtained from 864 GD patients and 864 control subjects for the population-based casecontrol study. All control subjects had tests of thyroid function and autoantibody status, and any showing evidence of subclinical ATD were removed from the study before genotyping. All patients gave informed written consent and the project was approved by the local ethics committee. Clinical information on this data set has been published previously. 34 Genotyping-PCR-RFLP DNA was extracted from 10 ml whole blood using the Nucleon Bacc II Kit (Tepnel Life Sciences, UK).
Genotyping of the SNPs at positions -863, À308, À244 and -238 was carried out as previously described. [35] [36] [37] Amplicons containing the SNPs at positions -575, À572, À419, À163, À49, þ 492 and þ 851 were amplified using primers (Sigma-Genosys, UK) as shown in Table 5 in a MJ Research, Inc. Tetrad thermal cycler. Products were visualised on a 2% agarose gel and then subjected to restriction fragment length polymorphism (RFLP) with appropriate enzymes (Table 5 ) under the manufacturers' conditions (New England Biolabs, UK & Helena Biosciences, UK). The products were then visualised on a 3% agarose gel and genotypes were assigned accordingly.
Genotyping-allele specific PCR Genotyping of SNPs at positions À1073, À1031, À857, À376, þ 467, þ 489, þ 943and þ 1304 was carried out by allele specific PCR as previously described, 38, 39 with stringent control primers being used in all allele specific PCR reactions to ensure that the absence of an allele was not due to PCR failure of that particular reaction.
Genotyping-sequencing
SNPs at positions þ 69, þ 70 and þ 691 were genotyped by direct sequencing. PCR was performed using primers as detailed in Table 5 and sequencing was carried out on an ABI377 automated sequencer using BigDyet Terminator Cycle sequence ready reaction kits (Applied Biosystems, Warrington, UK). Results were analysed using DNA Sequencing software version 2.10 (Applied Biosystems, Warrington, UK).
HLA-DRB1, DQB1 and DQA1 typing All samples had been previously genotyped for HLA-DRB1, DQB1 and DQA1 using the phototyping method of PCR as previously published. 40 42 Power calculations were performed using a computer program provided by Heather Cordell, University of Cambridge, UK.
Statistical analysis
